Quarterly Activity Report and Appendix 4C for 31 December 2021

Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2021. The announcement highlights a recap of the…


Biotech Daily — Dr Boreham's Crucible: Imagion Biosystems

Tim Boreham revisits Imagion Biosystems' potential in this 5-1/2 page article profiling the company and discussing its recent milestones. Read the article…


Imagion Biosystems December 2021 Investor Newsletter

We are pleased to provide our investors with our December 2021 Investor Newsletter. In this edition, our Executive Director and CEO Bob Proulx gives an…


Employee Spotlight: Carmen Soikowski, Director of Operations

Highlighting our dedicated employees who bring both their experience and passions to Imagion Biosystems:  We sat down with Carmen Soikowski, who joined us as…


IBXO Options Exercise Complete

Imagion Biosystems is pleased to advise that it has now received the full $4.8 million from the exercise of all 96,706,395 listed options (IBXO) which had an…


Magnetic Nanoparticles as Imaging Agents Presentation at the 2021 VBIC Meeting

As a sponsor of the 2021 Annual VBIC Network Meeting, Imagion Biosystems' President and CEO, Bob Proulx, gave a presentation on magnetic nanoparticles as…


IBXO Options Underwriting Agreement — US Based Investor

Imagion Biosystems is pleased to announce it has entered into an options underwriting agreement (Underwriting Agreement) with Mercer Street Global…


Quarterly Activity Report — Quarter Ending 30 September 2021

Q3 highlights: Sites added for MagSense® HER2 Breast Cancer Phase I Study Experienced Chief Development Officer added to Management Team Joint Development…


Q&A with Chief Development Officer Yalia Jayalakshmi, Ph.D.

In this video, Chief Development Officer Yalia Jayalakshmi, Ph.D. explains why she joined Imagion Biosystems, the urgency of the company's mission, and the…


Supplementary Announcement IBX / Global Cancer Technology

Further to the announcement made on 13th August 2021, Imagion Biosystems Limited provides this supplementary announcement in relation to the agreement with…